November 24, 2023
A batch of potentially big-selling medicines reached the Japanese market on November 22 upon their reimbursement listing, including Chugai Pharmaceutical’s combination cancer drug Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa). Phesgo is a fixed-dose subcutaneous combination of Perjeta (pertuzumab) and...read more